Serum Biomarkers of Inflammation, Fibrosis, and Cardiac Function in Facilitating Diagnosis, Prognosis, and Treatment of Anti-SSA/Ro–Associated Cardiac Neonatal Lupus

Documenti analoghi

• Maternal and Fetal Factors Associated with Mortality and Morbidity in a Multi-Racial/Ethnic Registry of Anti-SSA/Ro Associated Cardiac Neonatal Lupus
  di: Izmirly, Peter M., et al.
  Pubblicazione: (2011)
• Maternal Use of Hydroxychloroquine is Associated with a Reduced Risk of Recurrent Anti-SSA/Ro Associated Cardiac Manifestations of Neonatal Lupus
  di: Izmirly, Peter M., et al.
  Pubblicazione: (2012)
• Umbilical Cord Blood Levels of Maternal Antibodies Reactive with p200 and Full Length Ro52 in the Assessment of Risk for Cardiac Manifestations of Neonatal Lupus: Ro52 p200 Antibodies in Cardiac Neonatal Lupus
  di: Reed, Joanne H., et al.
  Pubblicazione: (2012)
• Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system
  di: Izmirly, Peter M, et al.
  Pubblicazione: (2015)
• Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus
  di: Izmirly, Peter, et al.
  Pubblicazione: (2017)